Melanotan II: Mechanism, Research, and Regulatory Status

Melanotan II is not approved as a pharmaceutical in any jurisdiction and is classified as WADA S2 prohibited. Multiple regulatory agencies including the FDA, EMA, and TGA have issued warnings about unlicensed use. For research purposes only.

Bremelanotide (PT-141) is derived from Melanotan II research and is a selective MC4R agonist that received FDA approval for hypoactive sexual desire disorder (HSDD) in 2019. Unlike Melanotan II, bremelanotide was redesigned for selective MC3R/MC4R activity with reduced MC1R activity to minimize tanning effects.

Melanotan I and afamelanotide are the same molecule under two names: a linear alpha-MSH analog marketed as Scenesse and approved in the US and EU for erythropoietic protoporphyria. Melanotan II is a different compound entirely, a cyclic heptapeptide with broad non-selective activity across MC1R through MC5R, and it is approved nowhere. The three names are used interchangeably in casual discussion, which is wrong and matters: only one has an approved indication and a controlled safety dataset.

Nausea is the dose-limiting effect across the human literature, reported in roughly half of subjects at higher doses in the original Phase 1 work. It is attributed to central melanocortin activity rather than a peripheral or injection-site effect, which is why it scales with dose and does not resolve with a change of injection site.

This is the most serious open question. MC1R agonism acts directly on melanocytes, and dermatology case reports and reviews document darkening, enlargement and eruptive appearance of nevi during use. A causal link to melanoma has not been established, but it also has not been excluded, and the mechanism gives a plausible route. Reviews in the dermatological literature (Langan 2010) treat it as an unresolved safety concern rather than a theoretical one.

It has never completed a development program, so no regulator has assessed it for safety or efficacy, and it is sold outside the pharmaceutical supply chain entirely. The FDA, EMA and TGA have all issued consumer warnings about unlicensed melanotan products. That absence of oversight also means composition and purity vary between suppliers, which is precisely why batch-level analytical documentation matters for research material.

Melanogenesis is stimulated directly through MC1R rather than requiring UV, which is the pharmacological basis of the compound. This is often presented as making it a safer alternative to sun exposure, a claim the published literature does not support: it removes the UV stimulus but adds an unapproved systemic peptide with a documented adverse-effect profile.